BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yan T, Yan N, Wang P, Xia Y, Hao H, Wang G, Gonzalez FJ. Herbal drug discovery for the treatment of nonalcoholic fatty liver disease. Acta Pharm Sin B 2020;10:3-18. [PMID: 31993304 DOI: 10.1016/j.apsb.2019.11.017] [Cited by in Crossref: 57] [Cited by in F6Publishing: 43] [Article Influence: 28.5] [Reference Citation Analysis]
Number Citing Articles
1 Li YM, Zhao SY, Zhao HH, Wang BH, Li SM. Procyanidin B2 Alleviates Palmitic Acid-Induced Injury in HepG2 Cells via Endoplasmic Reticulum Stress Pathway. Evid Based Complement Alternat Med 2021;2021:8920757. [PMID: 34956386 DOI: 10.1155/2021/8920757] [Reference Citation Analysis]
2 Chen Y, Jiang Z, Xu J, Zhang J, Sun R, Zhou J, Lu Y, Gong Z, Huang J, Shen X, Du Q, Peng J. Improving the ameliorative effects of berberine and curcumin combination via dextran-coated bilosomes on non-alcohol fatty liver disease in mice. J Nanobiotechnology 2021;19:230. [PMID: 34348707 DOI: 10.1186/s12951-021-00979-1] [Reference Citation Analysis]
3 Gerges SH, Wahdan SA, Elsherbiny DA, El-Demerdash E. Non-alcoholic fatty liver disease: An overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions. Life Sci 2021;271:119220. [PMID: 33592199 DOI: 10.1016/j.lfs.2021.119220] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
4 Ji L, Li Q, He Y, Zhang X, Zhou Z, Gao Y, Fang M, Yu Z, Rodrigues RM, Gao Y, Li M. Therapeutic potential of traditional Chinese medicine for the treatment of NAFLD: a promising drug Potentilla discolor Bunge. Acta Pharmaceutica Sinica B 2022. [DOI: 10.1016/j.apsb.2022.05.001] [Reference Citation Analysis]
5 Cui Y, Wang Q, Chang R, Aboragah A, Loor JJ, Xu C. Network Pharmacology-Based Analysis of Pogostemon cablin (Blanco) Benth Beneficial Effects to Alleviate Nonalcoholic Fatty Liver Disease in Mice. Front Pharmacol 2021;12:789430. [PMID: 34899351 DOI: 10.3389/fphar.2021.789430] [Reference Citation Analysis]
6 Li P, Chen Y, Ke X, Zhang R, Zuo L, Wang M, Chen Z, Luo X, Wang J. Baicalin ameliorates alcohol-induced hepatic steatosis by suppressing SREBP1c elicited PNPLA3 competitive binding to ATGL. Archives of Biochemistry and Biophysics 2022;722:109236. [DOI: 10.1016/j.abb.2022.109236] [Reference Citation Analysis]
7 Hamada K, Wang P, Xia Y, Yan N, Takahashi S, Krausz KW, Hao H, Yan T, Gonzalez FJ. Withaferin A alleviates ethanol-induced liver injury by inhibiting hepatic lipogenesis. Food Chem Toxicol 2022;160:112807. [PMID: 34995708 DOI: 10.1016/j.fct.2022.112807] [Reference Citation Analysis]
8 Ara SA, Ahmad B, Fazil M, Akhlaq S, Akram U, Haque M, Khan AA. Izkhar [Cymbopogon martinii (Roxb.)] Wats.: An Evidence-based Review on its Phytochemical Aspect and Hepatoprotective Traditional Use in Unani Medicine. Journal of Herbal Medicine 2022. [DOI: 10.1016/j.hermed.2022.100576] [Reference Citation Analysis]
9 Jin M, Wei Y, Yu H, Ma X, Yan S, Zhao L, Ding L, Cheng J, Feng H. Erythritol Improves Nonalcoholic Fatty Liver Disease by Activating Nrf2 Antioxidant Capacity. J Agric Food Chem 2021;69:13080-92. [PMID: 34719928 DOI: 10.1021/acs.jafc.1c05213] [Reference Citation Analysis]
10 Gong X, Li T, Wan R, Sha L. Cordycepin attenuates high-fat diet-induced non-alcoholic fatty liver disease via down-regulation of lipid metabolism and inflammatory responses. Int Immunopharmacol 2021;91:107173. [PMID: 33352441 DOI: 10.1016/j.intimp.2020.107173] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
11 Zhang W, Lin H, Cheng W, Huang Z, Zhang W. Protective Effect and Mechanism of Plant-Based Monoterpenoids in Non-alcoholic Fatty Liver Diseases. J Agric Food Chem 2022;70:4839-59. [PMID: 35436113 DOI: 10.1021/acs.jafc.2c00744] [Reference Citation Analysis]
12 Lou YY, Zheng X, Huang YP, Mu L, Zhang XG, Zhao ZW, Song Z, Zhang J, Yin ZQ, Pan K. New dammarane-type triterpenoid saponins from Gynostemma pentaphyllum and their Sirt1 agonist activity. Bioorg Chem 2021;116:105357. [PMID: 34562675 DOI: 10.1016/j.bioorg.2021.105357] [Reference Citation Analysis]
13 Bansod S, Saifi MA, Godugu C. Molecular updates on berberine in liver diseases: Bench to bedside. Phytother Res 2021. [PMID: 34056769 DOI: 10.1002/ptr.7181] [Reference Citation Analysis]
14 Wu S, Liu D, Li W, Song B, Chen C, Chen D, Hu H. Enhancing TNBC Chemo-immunotherapy via combination reprogramming tumor immune microenvironment with Immunogenic Cell Death. Int J Pharm 2021;598:120333. [PMID: 33540008 DOI: 10.1016/j.ijpharm.2021.120333] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
15 Sun Q, Niu Q, Guo Y, Zhuang Y, Li X, Liu J, Li N, Li Z, Huang F, Qiu Z. Regulation on Citrate Influx and Metabolism through Inhibiting SLC13A5 and ACLY: A Novel Mechanism Mediating the Therapeutic Effects of Curcumin on NAFLD. J Agric Food Chem 2021;69:8714-25. [PMID: 34323067 DOI: 10.1021/acs.jafc.1c03105] [Reference Citation Analysis]
16 Zhu Y, Zhang X, Du P, Wang Z, Luo P, Huang Y, Liu Z, Zhang H, Chen W. Dietary herbaceous mixture supplementation reduced hepatic lipid deposition and improved hepatic health status in post-peak laying hens. Poultry Science 2022. [DOI: 10.1016/j.psj.2022.101870] [Reference Citation Analysis]
17 Lan T, Jiang S, Zhang J, Weng Q, Yu Y, Li H, Tian S, Ding X, Hu S, Yang Y, Wang W, Wang L, Luo D, Xiao X, Piao S, Zhu Q, Rong X, Guo J. Breviscapine alleviates NASH by inhibiting TGF-β-activated kinase 1-dependent signaling. Hepatology 2021. [PMID: 34717002 DOI: 10.1002/hep.32221] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
18 Li Y, Liu Y, Yang M, Wang Q, Zheng Y, Xu J, Zheng P, Song H. A Study on the Therapeutic Efficacy of San Zi Yang Qin Decoction for Non-Alcoholic Fatty Liver Disease and the Underlying Mechanism Based on Network Pharmacology. Evid Based Complement Alternat Med 2021;2021:8819245. [PMID: 33505505 DOI: 10.1155/2021/8819245] [Reference Citation Analysis]
19 Man S, Luo C, Yan M, Zhao G, Ma L, Gao W. Treatment for liver cancer: From sorafenib to natural products. Eur J Med Chem 2021;224:113690. [PMID: 34256124 DOI: 10.1016/j.ejmech.2021.113690] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Moszak M, Szulińska M, Walczak-Gałęzewska M, Bogdański P. Nutritional Approach Targeting Gut Microbiota in NAFLD-To Date. Int J Environ Res Public Health 2021;18:1616. [PMID: 33567710 DOI: 10.3390/ijerph18041616] [Reference Citation Analysis]
21 Li X, Chen XX, Xu Y, Xu XB, Wu WF, Zhao Q, Hu JN. Construction of Glycogen-Based Nanoparticles Loaded with Resveratrol for the Alleviation of High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease. Biomacromolecules 2021. [PMID: 34964604 DOI: 10.1021/acs.biomac.1c01360] [Reference Citation Analysis]
22 Wang T, Liu J, Luo X, Hu L, Lu H. Functional metabolomics innovates therapeutic discovery of traditional Chinese medicine derived functional compounds. Pharmacol Ther 2021;224:107824. [PMID: 33667524 DOI: 10.1016/j.pharmthera.2021.107824] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
23 Tang R, Li R, Li H, Ma XL, Du P, Yu XY, Ren L, Wang LL, Zheng WS. Design of Hepatic Targeted Drug Delivery Systems for Natural Products: Insights into Nomenclature Revision of Nonalcoholic Fatty Liver Disease. ACS Nano 2021. [PMID: 34705426 DOI: 10.1021/acsnano.1c02158] [Reference Citation Analysis]
24 Yang XF, Lu M, You L, Gen H, Yuan L, Tian T, Li CY, Xu K, Hou J, Lei M. Herbal therapy for ameliorating nonalcoholic fatty liver disease via rebuilding the intestinal microecology. Chin Med 2021;16:62. [PMID: 34315516 DOI: 10.1186/s13020-021-00470-x] [Reference Citation Analysis]
25 Ma X, Zhang T, Luo Z, Li X, Lin M, Li R, Du P, Yu X, Ma C, Yan P, Su J, Wang L, Li Y, Jiang J. Functional nano-vector boost anti-atherosclerosis efficacy of berberine in Apoe (-/-) mice. Acta Pharm Sin B 2020;10:1769-83. [PMID: 33088695 DOI: 10.1016/j.apsb.2020.03.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
26 Tong J, Li D, Meng H, Sun D, Lan X, Ni M, Ma J, Zeng F, Sun S, Fu J, Li G, Ji Q, Zhang G, Shen Q, Wang Y, Zhu J, Zhao Y, Wang X, Liu Y, Ouyang S, Sheng C, Shen F, Wang P. Targeting a novel inducible GPX4 alternative isoform to alleviate ferroptosis and treat metabolic-associated fatty liver disease. Acta Pharmaceutica Sinica B 2022. [DOI: 10.1016/j.apsb.2022.02.003] [Reference Citation Analysis]
27 Xia Y, Wang P, Yan N, Gonzalez FJ, Yan T. Withaferin A alleviates fulminant hepatitis by targeting macrophage and NLRP3. Cell Death Dis 2021;12:174. [PMID: 33574236 DOI: 10.1038/s41419-020-03243-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Ballway JW, Song BJ. Translational Approaches with Antioxidant Phytochemicals against Alcohol-Mediated Oxidative Stress, Gut Dysbiosis, Intestinal Barrier Dysfunction, and Fatty Liver Disease. Antioxidants (Basel) 2021;10:384. [PMID: 33806556 DOI: 10.3390/antiox10030384] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
29 Jiang D, Zhang J, Lin S, Wang Y, Chen Y, Fan J. Prolyl Endopeptidase Gene Disruption Improves Gut Dysbiosis and Non-alcoholic Fatty Liver Disease in Mice Induced by a High-Fat Diet. Front Cell Dev Biol 2021;9:628143. [PMID: 34095107 DOI: 10.3389/fcell.2021.628143] [Reference Citation Analysis]
30 Yan T, Luo Y, Xia Y, Hamada K, Wang Q, Yan N, Krausz KW, Ward JM, Hao H, Wang P, Gonzalez FJ. St. John's Wort alleviates dextran sodium sulfate-induced colitis through pregnane X receptor-dependent NFκB antagonism. FASEB J 2021;35:e21968. [PMID: 34644426 DOI: 10.1096/fj.202001098R] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Li L, Li S, Jiang J, Liu C, Ji L. Investigating pharmacological mechanisms of andrographolide on non-alcoholic steatohepatitis (NASH): A bioinformatics approach of network pharmacology. Chinese Herbal Medicines 2021;13:342-50. [DOI: 10.1016/j.chmed.2021.05.001] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Bhave S, Ho HK. Exploring the Gamut of Receptor Tyrosine Kinases for Their Promise in the Management of Non-Alcoholic Fatty Liver Disease. Biomedicines 2021;9:1776. [PMID: 34944593 DOI: 10.3390/biomedicines9121776] [Reference Citation Analysis]
33 Cui S, Pan XJ, Ge CL, Guo YT, Zhang PF, Yan TT, Zhou JY, He QX, Cheng LH, Wang GJ, Hao HP, Wang H. Silybin alleviates hepatic lipid accumulation in methionine-choline deficient diet-induced nonalcoholic fatty liver disease in mice via peroxisome proliferator-activated receptor α. Chin J Nat Med 2021;19:401-11. [PMID: 34092291 DOI: 10.1016/S1875-5364(21)60039-0] [Reference Citation Analysis]
34 Ding L, Yang Q, Zhang E, Wang Y, Sun S, Yang Y, Tian T, Ju Z, Jiang L, Wang X, Wang Z, Huang W, Yang L. Notoginsenoside Ft1 acts as a TGR5 agonist but FXR antagonist to alleviate high fat diet-induced obesity and insulin resistance in mice. Acta Pharm Sin B 2021;11:1541-54. [PMID: 34221867 DOI: 10.1016/j.apsb.2021.03.038] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
35 Xu L, Yin L, Qi Y, Tan X, Gao M, Peng J. 3D disorganization and rearrangement of genome provide insights into pathogenesis of NAFLD by integrated Hi-C, Nanopore, and RNA sequencing. Acta Pharm Sin B 2021;11:3150-64. [PMID: 34729306 DOI: 10.1016/j.apsb.2021.03.022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Zhou H, Ma C, Wang C, Gong L, Zhang Y, Li Y. Research progress in use of traditional Chinese medicine monomer for treatment of non-alcoholic fatty liver disease. Eur J Pharmacol 2021;898:173976. [PMID: 33639194 DOI: 10.1016/j.ejphar.2021.173976] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Zheng X, Zhang X, Liu Y, Zhu L, Liang X, Jiang H, Shi G, Zhao Y, Zhao Z, Teng Y, Pan K, Zhang J, Yin Z. Arjunolic acid from Cyclocarya paliurus ameliorates nonalcoholic fatty liver disease in mice via activating Sirt1/AMPK, triggering autophagy and improving gut barrier function. Journal of Functional Foods 2021;86:104686. [DOI: 10.1016/j.jff.2021.104686] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Zhang Y, Yan T, Wang T, Liu X, Hamada K, Sun D, Sun Y, Yang Y, Wang J, Takahashi S, Wang Q, Krausz KW, Jiang C, Xie C, Yang X, Gonzalez FJ. Crosstalk between CYP2E1 and PPARα substrates and agonists modulate adipose browning and obesity. Acta Pharm Sin B 2022;12:2224-38. [PMID: 35646522 DOI: 10.1016/j.apsb.2022.02.004] [Reference Citation Analysis]
39 Im HJ, Hwang SJ, Lee JS, Lee SB, Kang JY, Son CG. Ethyl Acetate Fraction of Amomum xanthioides Ameliorates Nonalcoholic Fatty Liver Disease in a High-Fat Diet Mouse Model. Nutrients 2020;12:E2433. [PMID: 32823613 DOI: 10.3390/nu12082433] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
40 Drygalski K, Siewko K, Chomentowski A, Odrzygóźdź C, Zalewska A, Krętowski A, Maciejczyk M. Phloroglucinol Strengthens the Antioxidant Barrier and Reduces Oxidative/Nitrosative Stress in Nonalcoholic Fatty Liver Disease (NAFLD). Oxid Med Cell Longev 2021;2021:8872702. [PMID: 33510844 DOI: 10.1155/2021/8872702] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
41 Abou Assi R, Abdulbaqi IM, Siok Yee C. The Evaluation of Drug Delivery Nanocarrier Development and Pharmacological Briefing for Metabolic-Associated Fatty Liver Disease (MAFLD): An Update. Pharmaceuticals (Basel) 2021;14:215. [PMID: 33806527 DOI: 10.3390/ph14030215] [Reference Citation Analysis]
42 Susilowati R, Setiawan AM, Zahroh AF, Ashari ZN, Iffiyana A, Hertanto R, Basyarudin M, Hartiningsih I, Ismail M. Hepatoprotection of Cinnamomum burmannii ethanolic extract against high-fat and cholesterol diet in Sprague–Dawley rats (Rattus norvegicus). Vet World. [DOI: 10.14202/vetworld.2022.930-936] [Reference Citation Analysis]
43 Chen H, Nie T, Zhang P, Ma J, Shan A. Hesperidin attenuates hepatic lipid accumulation in mice fed high-fat diet and oleic acid induced HepG2 via AMPK activation. Life Sci 2022;:120428. [PMID: 35218767 DOI: 10.1016/j.lfs.2022.120428] [Reference Citation Analysis]
44 Xue JJ, Jiang CY, Zou DL, Li BJ, Lu JC, Li DH, Lin B, Li ZL, Hua HM. Baicalensines A and B, Two Isoquinoline Alkaloids from the Roots of Thalictrum baicalense. Org Lett 2020;22:7439-42. [PMID: 32886519 DOI: 10.1021/acs.orglett.0c02444] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]